A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to determine whether fish oil (containing omega-3 fatty acids) given enterally is safe and effective in reducing lung and systemic inflammation seen in acute lung injury.
Full description
Acute lung injury (ALI) is common among critically ill patients and is associated with a high case fatality. Only one intervention has been shown to improve survival in a large clinical trial, and new therapies targeting the inflammatory response are needed. Nutrient interventions may provide benefit; specifically there is plausible biologic rationale for administering n-3 fatty acids (n-3 FAs) found in fish oil to patients with ALI, as n-3 FAs decrease formation of eicosanoid inflammatory mediators. However, although promising results have emerged from prior studies, fish oils have only been tested in ALI patients in a commercial enteral formula containing additional nutrients, and the control group received a high-fat enteral formula that may have been proinflammatory. Therefore, no conclusion can be drawn about the independent effect of fish oils. Furthermore, the inclusion of key pharmaconutrients in feeding formulas, instead of delivering them separately as pharmaceuticals, limits exposure to the agent, as intensive care unit (ICU) patients commonly receive less than 60% of prescribed caloric needs. Finally, specialized feeding formulas are very expensive, and it may be substantially cheaper to administer pharmaconutrients separately. We believe it is time to begin to approach nutrient trials in critically ill patients differently -- to move away from including them in feeding formulas and begin delivering them like pharmaceuticals. With appropriate scientific investigation and the use of non-nutrient placebos, this novel and innovative approach is a new paradigm of investigating nutrient delivery to critically ill patients.
This study is a phase II randomized controlled trial to determine the effects of enteral eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA), both n-3 FAs found in fish oil, versus placebo on the pulmonary and systemic environments, and on clinical outcomes, in patients with ALI. We will investigate the effect of fish oil administration on several biological markers of injury and inflammation in bronchoalveolar lavage fluid and serum, on pulmonary physiologic outcomes, and on clinical outcomes.
Comparison(s): Mechanically ventilated patients with acute lung injury randomized to receive enteral fish oil versus compared to mechanically ventilated patients with acute lung injury randomized to receive placebo.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Requiring positive-pressure mechanical ventilation
- ALI criteria: PaO2/FiO2 <300, bilateral infiltrates on chest radiograph, no left atrial hypertension
- Age > 17 years
Exclusion criteria
- Expected ICU length of stay <48 hours
- Unable to undergo bronchoalveolar lavage at enrollment
- Unable to obtain enteral access
- Post-cardiac arrest with suspected significant anoxic brain injury
- Expected survival < 28 days
- Pregnant
- Platelet count < 30,000, active bleeding, or international normalized ratio (INR)>3.0
- History of ventricular tachycardia or fibrillation
- Receiving recombinant human activated protein C (rh-APC) for sepsis
- Acquired immune deficiency syndrome (AIDS) with CD4 count < 200
- Metastatic cancer
- History of bone marrow, lung, liver, cardiac, kidney, or pancreas transplant
Trial design
Primary purpose
Allocation
Interventional model
Masking
90 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal